Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,548 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Surgery Clear all
Terminated Phase 2 Interventional Results available

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

NCT03570476
View directory record Official record
Conditions
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Olaparib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Devices Used in Fetoscopic Neural Tube Defect Repair Cases

NCT05672849
View directory record Official record
Conditions
Neural Tube Defects
Interventions
Modified Surgical Instruments/Devices (Sheaths and Irrigator)
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

NCT05674825
View directory record Official record
Conditions
Cancer
Interventions
Targeted agent, Standard of care agent
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149
View directory record Official record
Conditions
Solid Tumor
Interventions
STP707
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT03346135
View directory record Official record
Conditions
Plasma Cell Myeloma, Secondary Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis, Melphalan
Procedure · Biological · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Duarte, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 3 Interventional

The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal

NCT07142408
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Chlorhexidine gluconate (4%), Mupirocin 2% Ointment
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 4 Interventional

Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters

NCT05972018
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal, Abdominal Aortic Occlusion, Aortoiliac Occlusive Disease, Aortic Diseases
Interventions
Liposomal bupivacaine, Ropivacaine, Bupivacain
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

NCT01234935
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method
Drug · Other · Genetic
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Alhambra, California • Fullerton, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466
View directory record Official record
Conditions
Chronic Intractable Pain
Interventions
Intraspinal Gabapentin
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 30, 2026, 10:11 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

NCT02997956
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tocilizumab, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Preventing Weight Gain and Unhealthy Behaviors in Children

NCT04608188
View directory record Official record
Conditions
Obesity
Interventions
Summer Camp
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
5 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

NCT06639594
View directory record Official record
Conditions
Impulse Control Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Levofloxacin Ocular Implant for Ocular Surgery

NCT04682288
View directory record Official record
Conditions
Cataract
Interventions
Levofloxacin Ocular Implant
Drug
Lead sponsor
PolyActiva Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
St Louis, Missouri • Ladson, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 30, 2026, 10:11 AM EDT
Not listed Not applicable Interventional

Sinus Tarsi Versus Extensile Lateral Approach for Calcaneus Fractures

NCT02446470
View directory record Official record
Conditions
Intra-articular Fractures
Interventions
Sinus Tarsi approach, Extensile Lateral approach
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated No phase listed Observational

Laparoscopic Vs. Open Prostatectomy Outcomes

NCT00695773
View directory record Official record
Conditions
Prostate Cancer Surgery
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

NCT01336959
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
BCT197 Part A, Placebo, BCT197 Part B
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

NCT01094496
View directory record Official record
Conditions
Bladder Cancer
Interventions
CDX-1307 Vaccine Regimen, Chemotherapy
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 30, 2026, 10:11 AM EDT
Withdrawn Not applicable Interventional

Study of Endoscopic Versus Open Surgery for Urinary Reflux

NCT00830479
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
Anti-reflux surgery, Endoscopic injection
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Phase 4 Interventional

Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque

NCT02316886
View directory record Official record
Conditions
Coronary Artery Disease, Plaque, Atherosclerotic
Interventions
Coronary intervention, Optimal Medical treatment
Device · Drug
Lead sponsor
Seung-Jung Park
Other
Eligibility
18 Years and older
Enrollment
1,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Study to Evaluate Implant Survival Rate of Astra Tech Fixture ST in the Posterior Maxilla With One-stage Surgery and Early Loading

NCT00748241
View directory record Official record
Conditions
Jaw, Edentulous, Partially
Interventions
Astra Tech Fixture ST
Device
Lead sponsor
Dentsply Sirona Implants and Consumables
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 30, 2026, 10:11 AM EDT
Terminated No phase listed Observational

Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy

NCT00912366
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Lobectomy
Procedure
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 30, 2026, 10:11 AM EDT